Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension

Zhang Wei; ZhuGe YuZheng; Zhang Ming; He QiBin; Zhang Feng; Wang Yi; Zou XiaoPing

doi:10.3969/j.issn.1001-5256.2016.02.012

Issue 2

Feb. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(2): 259-263

PDF( 704 KB)

Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension

DOI: 10.3969/j.issn.1001-5256.2016.02.012

Department of Gastroenterology,Affiliated Drum Tower Hospital of Nanjing University Medical School

Research funding:

Received Date: 2015-12-09
Published Date: 2016-02-20

Abstract

Abstract

Objective To investigate the short- term effect and safety of transjugular intrahepatic portosystemic shunt( TIPS) in the treatment of decompensated primary biliary cirrhosis( PBC). Methods The clinical data of 26 patients with decompensated PBC who received TIPS in Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2009 to May 2015 were analyzed retrospectively.The indicators including portal venous pressure,liver function,and survival before and after TIPS during 1 year of follow up were compared.The Friedman test was applied as the rank sum test for multiple related samples,the Wilcoxon test was applied as the paired rank sum test,and the Kaplan- Meier curve was applied for survival analysis. Results All patients had significantly reduced mean portal pressure after TIPS( 1911( 16. 35- 22. 05) mm Hg vs 27. 93( 25. 26- 30. 87) mm Hg; Z =- 4. 199,P < 0. 001). Within 3 months after TIPS,the patients showed significant increases in total bilirubin,Model for End- Stage Liver Disease score,and bile acid( χ2= 26. 000,18. 429,and16. 353,all P < 0. 001). The most common postoperative complication was pyrexia,which had an incidence rate of 80. 77%( 21 /26),followed by hepatic encephalopathy,with an incidence rate of 19. 23%( 7 /26). The survival rates at 6 and 12 months after surgery were both92. 3%( 24 /26). Conclusions TIPS has good short- to medium- term effect and safety in the treatment of decompensated PBC,and its long- term effect still needs to be proved.
- liver cirrhosis,biliary,
- portal hypertension,
- portasystemic shunt,transjugular intrahepatic

FullText(HTML)

References(15)

References

[1]CAREY EJ,ALI AH,LINDOR KD.Primary biliary cirrhosis[J].Lancet,2015,386(10003):1565-1575.

[2]RUDLER M,CLUZEL P,CORVEC TL,et al.Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding,without improving survival[J].Aliment Pharmacol Ther,2014,40(9):1074-1080.

[3]GARCIA-PAGAN JC,CACA K,BUREAU C,et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].N Engl J Med,2010,362(25):2370-2379.

[4]CHENG SP,XUE HL,ZENG WZ,et al.TIPS for treatment of gastro-intestinal bleeding in patients with liver cirrhosis:Analysis of232 cases[J].World Chin J Dig,2014,22(15):2163-2168.(in Chinese)程双平,薛红利,曾维政,等.TIPS手术治疗肝硬化消化系出血232例[J].世界华人消化杂志,2014,22(15):2163-2168.

[5]HEATHCOTE EJ.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J].Hepatology,2000,31(4):1005-1013.

[6]QI X,LIU L,BAI M,et al.Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding:a meta-analysis[J].J Gastroenterol Hepatol,2014,29(4):688-696.

[7]LI CQ,LI HL,GUO J,et al.Application of simulative viatorr technique in TIPS with double stents[J/CD].Chin J Liver Dis:Electronic Edition,2014,6(1):50-54.(in Chinese)李常青,李洪璐,郭江,等.双支架技术在TIPS治疗中的临床应用研究[J/CD].中国肝脏病杂志:电子版,2014,6(1):50-54.

[8]PERARNAU JM,LE GOUGE A,NICOLAS C,et al.Covered vs.uncovered stents for transjugular intrahepatic portosystemic shunt:a randomized controlled trial[J].J Hepatol,2014,60(5):962-968.

[9]LUCA A,MIRAGLIA R,CARUSO S,et al.Short-and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis[J].Gut,2011,60(6):846-852.

[10]YUAN SS.Long-term outcome and predictors of mortality after transjugular intrahepatic portosystemic shunt(TIPS)for variceal hemorrhage and refractory ascites[D].Xi'an:Fourth Military Medical University,2011.(in Chinese)原姗姗.TIPS治疗肝硬化静脉曲张出血和顽固性腹水的长期疗效和预后分析[D].西安:第四军医大学,2011.

[11]TRIPATHI D,LUI HF,HELMY A,et al.Randomised controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for preventing oesophageal variceal rebleeding[J].Gut,2004,53(3):431-437.

[12]CASADABAN LC,PARVINIAN A,COUTURE PM,et al.Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality[J].AJR Am J Roentgenol,2014,203(6):1363-1370.

[13]LAMMERS WJ,van BUUREN HR,HIRSCHFIELD GM,et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology,2014,147(6):1338-1349.

[14]CASADABAN LC,PARVINIAN A,MINOCHA J,et al.Clearing the confusion over hepatic encephalopathy after TIPS creation:incidence,prognostic factors,and clinical outcomes[J].Dig Dis Sci,2015,60(4):1059-1066.

[15]RIGGIO O,NARDELLI S,MOSCUCCI F,et al.Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J].Clin Liver Dis,2012,16(1):133-146.

Relative Articles

[1]	Minyue LI, Hongju YANG, Jing LI, Rui SONG, Jing YOU. Association of signal transducer and activator of transcription 3 and signal transducer and activator of transcription 5 with regulatory T cell/T helper 17 cell balance in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(6): 1393-1397. doi: 10.3969/j.issn.1001-5256.2022.06.036
[2]	Guangjun TANG, Jing YOU, Huai'e LIU, Yujuan PENG. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(2): 414-418. doi: 10.3969/j.issn.1001-5256.2021.02.035
[3]	Xue Miao, Mao XiaoRong, Chen Hong. Change in T helper 17 cell/regulatory T cell imbalance in rats with immunological liver injury[J]. Journal of Clinical Hepatology, 2020, 36(1): 149-152. doi: 10.3969/j.issn.1001-5256.2020.01.033
[4]	YANG JingShu, LI Ning. Research advances in T helper 17 cells in chronic inflammatory liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2808-2810. doi: 10.3969/j.issn.1001-5256.2020.12.034
[5]	Wang WeiZhao, Xiang XiaoXing. Immunological mechanism of Treg/Th17 and Th1/Th2 balance in autoimmune hepatitis and new targets for diagnosis and treatment[J]. Journal of Clinical Hepatology, 2019, 35(8): 1874-1877. doi: 10.3969/j.issn.1001-5256.2019.08.051
[6]	Deng WeiWei, Zhu WenMing, Yi Chao, Feng YangChun, Huang YanChun. Association of serum interleukin-17 level with early recurrence and prognosis after radical surgery in hepatocellular carcinoma patients with different levels of alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2018, 34(2): 298-302. doi: 10.3969/j.issn.1001-5256.2018.02.016
[7]	Yang JingYi, Cheng ShuQuan, Cao YaZhao, Huang ChengJun, Jiang FuMing. Expression of Toll-like receptors 2 and 3 in liver tissue and its clinical significance in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(2): 276-280. doi: 10.3969/j.issn.1001-5256.2018.02.012
[8]	Yang PuJuan, Huang Yi, Liu HuaBao. Research advances in the association between interleukin-17 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1810-1814. doi: 10.3969/j.issn.1001-5256.2017.09.041
[9]	Li KeXin, Zang MengYa, Wang DongMei, He Huan, Wang YuTing, Qu ChunFeng. Effect of interleukin-17A on stemness of hepatoma cell lines[J]. Journal of Clinical Hepatology, 2017, 33(6): 1131-1136. doi: 10.3969/j.issn.1001-5256.2017.06.023
[10]	Li XiaoTian, Yin Yan, Guo YongZe, Zhou LiYun, You ZiXuan. Mechanism of action of 1,25(OH)_2D_3 in influencing the expression of interleukin-17 and macrophage inflammatory protein-3α and inhibiting the formation of liver fibrosis in rats[J]. Journal of Clinical Hepatology, 2016, 32(12): 2331-2336. doi: 10.3969/j.issn.1001-5256.2016.12.020
[11]	Hao TingTing, Ma XiaoPeng, Wen YanLi, Dai GuangRong, Feng YiChao, Zhang Li. Changes in serum levels of M30,M65,and IL-17 and their clinical significance in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 329-332. doi: 10.3969/j.issn.1001-5256.2016.02.027
[12]	Cao ZhenHuan, Liu YaLi, Ma LiNa, Lu JunFeng, Jin Yi, He ZhiMin, Zheng YanHong, Chen XinYue. Association between serum level of interleukin-17 and HBsAg clearance in patients with HBsAg-negative chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1292-1295. doi: 10.3969/j.issn.1001-5256.2016.07.015
[13]	Li CaiDong, Yang YongWei, Li HuiJun, Tian PengFei, Wu Bin. Changes in peripheral plasma concentrations of macrophage migration inhibitory factor,interleukin-17,and interleukin-10 and their correlations with HBV DNA load in chronic HBV carriers[J]. Journal of Clinical Hepatology, 2015, 31(5): 702-705. doi: 10.3969/j.issn.1001-5256.2015.05.017
[14]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[15]	Liu ChaoHui, Chen YiJie, Zhang ChengHua. Effects of splenectomy on peripheral blood Th17 cells and immune function in patients with portal hypertension[J]. Journal of Clinical Hepatology, 2014, 30(9): 887-890. doi: 10.3969/j.issn.1001-5256.2014.09.012
[16]	Wei LinLin, Zhou Li, Shi HongBo, Duan ZhongPing. Role of Th17 cells in common liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(6): 477-480.
[17]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[18]	Hong YuBo, Zhang Ting, Sun LiGuang. Association between IL-2 +114 (G/T) polymorphism and susceptibility to hepatitis B, cirrhosis, and hepatocellular carcinoma in Jilin province[J]. Journal of Clinical Hepatology, 2012, 28(12): 930-933.
[19]	Qin JianJie, Lu: Ling. The role and molecular mechanism of interleukin-17 in organ transplant rejection[J]. Journal of Clinical Hepatology, 2012, 28(11): 812-814.
[20]	Yang Bo, Zhao CaiYan. Advanced research on Th17 cell and its relevant role in the progress liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(2): 206-209.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	周晓菊，邓威，杨丽. 医学检验科检查肝硬化疾病的临床应用价值. 黑龙江医学. 2024(11): 1340-1342 .
2.	张琳，冯晓彬，黄鑫，梁子威，何作祥，卢倩，董家鸿. 钇-90微球选择性内放射治疗在肝癌降期转化移植中的应用进展. 中华消化外科杂志. 2024(12): 1566-1570 .
3.	余敏，李歆. 528例卡瑞利珠单抗治疗的免疫相关不良反应及风险因素分析. 中国药物警戒. 2023(10): 1134-1140 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (372) PDF downloads(134)

Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension

DOI: 10.3969/j.issn.1001-5256.2016.02.012